Glaxo Augments OTCs With Stiefel Deal, Gains Strong Dermatology Foothold
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline will more than double its dermatology sales to $1.5 billion by acquiring Stiefel Laboratories and creating a global specialist business across Rx and OTC drugs
You may also be interested in...
Dermatology, Nasal Sprays Among Emerging OTC Switch Categories
FDA threw the switch floodgates open with the NSURE initiative and it has fueled interest with the recent first-in-class switches of Nasacort and Oxytrol for Women. Likely categories for successful switches include dermatology, nasal sprays in allergy, sleep, migraine relief and cholesterol management.
Dermatology, Nasal Sprays Among Emerging OTC Switch Categories
FDA threw the switch floodgates open with the NSURE initiative and it has fueled interest with the recent first-in-class switches of Nasacort and Oxytrol for Women. Likely categories for successful switches include dermatology, nasal sprays in allergy, sleep, migraine relief and cholesterol management.
Dermatology, Nasal Sprays Among Emerging OTC Switch Categories
FDA threw the switch floodgates open with the NSURE initiative and it has fueled interest with the recent first-in-class switches of Nasacort and Oxytrol for Women. Likely categories for successful switches include dermatology, nasal sprays in allergy, sleep, migraine relief and cholesterol management.